Jean-Daniel Lalau

Prof. Jean-Daniel Lalau


Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JLJean-Daniel Lalau
Jean-Daniel Lalau

5 January 2018 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JLJean-Daniel Lalau
Jean-Daniel Lalau
FKFarshad Kajbaf
Farshad Kajbaf
Youssef BennisYoussef Bennis
Youssef Bennis
AHAnne-Sophie Hurtel-Lemaire
Anne-Sophie Hurtel-Lemaire
FBFrans Belpaire
Frans Belpaire
MBMarc E. De Broe
Marc E. De Broe
OBJECTIVE This study was conducted to define a safe, effective dose regimen for metformin in moderate and severe chronic kidney disease (CKD; stages 3A/3B and 4, respectively), after the lifting of restrictions on metformin use in patients with diabetes with moderate-to-severe CKD in the absence of prospective safety and efficacy studies. RESEARCH DESIGN AND METHODS Three complementary studies were performed: 1) a dose-finding study in CKD stages 1–5, in which blood metformin concentrations were evaluated during a 1-week period after each dose increase; 2) a 4-month metformin treatment study for validating the optimal metformin dose as a function of the CKD stage (3A, 3B, and 4), with blood metformin, lactate, and HbA1c concentrations monitored monthly; and 3) an assessment of pharmacokinetic parameters after the administration of a single dose of metformin in steady-state CKD3A, 3B, and 4. RESULTS 1) In the dose-finding study, the appropriate daily dosing schedules were 1,500 mg (0.5 g in the morning [qam] +1 g in the evening [qpm]) in CKD3A, 1,000 mg (0.5 g qam + 0.5 g qpm) in CKD3B, and 500 mg (qam) in CKD4. 2) After 4 months on these regimens, patients displayed stable metformin concentrations that never exceeded the generally accepted safe upper limit of 5.0 mg/L. Hyperlactatemia (>5 mmol/L) was absent (except in a patient with myocardial infarction), and HbA1c levels did not change. 3) There were no significant differences in pharmacokinetic parameters among the CKD stage groups. CONCLUSIONS Provided that the dose is adjusted for renal function, metformin treatment appears to be safe and still pharmacologically efficacious in moderate-to-severe CKD.

2 September 2015 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
FKFarshad Kajbaf
Farshad Kajbaf
MBMarc E. De Broe
Marc E. De Broe
JLJean-Daniel Lalau
Jean-Daniel Lalau

11 July 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
JLJean-Daniel Lalau
Jean-Daniel Lalau
FKFarshad Kajbaf
Farshad Kajbaf
APAlessandro Protti
Alessandro Protti
MCMette M. Christensen
Mette M. Christensen
MBMarc E. De Broe
Marc E. De Broe
NWNicolas Wiernsperger
Nicolas Wiernsperger

1 September 2021 in Diabetes & Metabolism
Verified
Journal Article
Closed access
JLJean-Daniel Lalau
Jean-Daniel Lalau
AAAbdallah Al-Salameh
Abdallah Al-Salameh
SHSamy Hadjadj
Samy Hadjadj
TGThomas Goronflot
Thomas Goronflot
NWNicolas Wiernsperger
Nicolas Wiernsperger
BCBertrand Cariou
Bertrand Cariou

1 June 2011 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
JLJean-Daniel Lalau
Jean-Daniel Lalau
ALAnne-Sophie Lemaire-Hurtel
Anne-Sophie Lemaire-Hurtel
CLChristian Lacroix
Christian Lacroix